| MHC-I genotype restricts the oncogenic mutational landscape R Marty, S Kaabinejadian, D Rossell, MJ Slifker, J van de Haar, HB Engin, ... Cell 171 (6), 1272-1283. e15, 2017 | 332 | 2017 |
| Evolutionary pressure against MHC class II binding cancer mutations RM Pyke, WK Thompson, RM Salem, M Zanetti, H Carter Cell 175 (2), 416-428. e13, 2018 | 206 | 2018 |
| Interaction landscape of inherited polymorphisms with somatic events in cancer H Carter, R Marty, M Hofree, AM Gross, J Jensen, KM Fisch, X Wu, ... Cancer discovery 7 (4), 410-423, 2017 | 150 | 2017 |
| Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes A Castro, K Ozturk, RM Pyke, S Xian, M Zanetti, H Carter BMC medical genomics 12, 1-13, 2019 | 92 | 2019 |
| MHC-I genotype and tumor mutational burden predict response to immunotherapy AM Goodman, A Castro, RM Pyke, R Okamura, S Kato, P Riviere, ... Genome medicine 12, 1-13, 2020 | 86 | 2020 |
| Integrative genomic analysis of mouse and human hepatocellular carcinoma M Dow, RM Pyke, BY Tsui, LB Alexandrov, H Nakagawa, K Taniguchi, ... Proceedings of the National Academy of Sciences 115 (42), E9879-E9888, 2018 | 85 | 2018 |
| Strength of immune selection in tumors varies with sex and age A Castro, RM Pyke, X Zhang, WK Thompson, CP Day, LB Alexandrov, ... Nature communications 11 (1), 4128, 2020 | 84 | 2020 |
| Prediction of immunotherapy response in melanoma through combined modeling of neoantigen burden and immune-related resistance mechanisms CW Abbott, SM Boyle, RM Pyke, LD McDaniel, E Levy, FCP Navarro, ... Clinical Cancer Research 27 (15), 4265-4276, 2021 | 36 | 2021 |
| Precision neoantigen discovery using large-scale immunopeptidomes and composite modeling of MHC peptide presentation RM Pyke, D Mellacheruvu, S Dea, CW Abbott, SV Zhang, NA Phillips, ... Molecular & Cellular Proteomics 20, 2021 | 35 | 2021 |
| Immune DNA signature of T-cell infiltration in breast tumor exomes E Levy, R Marty, V Gárate Calderón, B Woo, M Dow, R Armisen, H Carter, ... Scientific reports 6 (1), 30064, 2016 | 31 | 2016 |
| Interaction landscape of inherited polymorphisms with somatic events in cancer. Cancer Discov. 2017; 7: 410–423. doi: 10.1158/2159-8290 H Carter, R Marty, M Hofree, AM Gross, J Jensen, KM Fisch, X Wu, ... CD-16-1045.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 26 | |
| High-‐resolution shot capture reveals systematic biases and an improved method for shooter evaluation R Marty | 11 | 2018 |
| A data-driven method for understanding and increasing 3-point shooting percentage R Marty, S Lucey MIT Sloan Sports Analytics Conference, 2017 | 10 | 2017 |
| A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity RM Pyke, D Mellacheruvu, S Dea, CW Abbott, L McDaniel, DP Bhave, ... Nature Communications 13 (1), 1925, 2022 | 9 | 2022 |
| MHC-I genotype drives early immune selection of oncogenic mutations R Marty, N De Prisco, H Carter, J Font-Burgada Molecular & cellular oncology 5 (2), e1409863, 2018 | 5 | 2018 |
| A high sensitivity, tumor-informed liquid biopsy platform, designed to detect minimal residual disease at part per million resolution SM Boyle, G Bartha, J Lyle, J Harris, J Northcott, D Norton, RM Pyke, ... Cancer Research 82 (12_Supplement), 5163-5163, 2022 | 3 | 2022 |
| Association of HLA loss of heterozygosity with allele-specific neoantigen expansion in response to immunotherapy. RM Pyke, C Abbott, S Dea, N Bedi, AD Colevas, E Levy, SV Zhang, ... Journal of Clinical Oncology 39 (15_suppl), e18030-e18030, 2021 | 3 | 2021 |
| P04. 02 A high sensitivity, tumor-informed liquid biopsy platform, designed to detect minimum residual disease at part per million resolution M Pruess, E Newburn, SM Boyle, D Norton, RM Pyke, F Navarro, J West, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 1), 2022 | 2 | 2022 |
| Computational KIR copy number discovery reveals interaction between inhibitory receptor burden and survival RM Pyke, R Genolet, A Harari, G Coukos, D Gfeller, H Carter Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 24, 148, 2019 | 2 | 2019 |
| Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay J Northcott, G Bartha, J Harris, C Li, FCP Navarro, RM Pyke, M Hong, ... Oncotarget 15, 200, 2024 | 1 | 2024 |
